67 Telaprevir With Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and Treatment in CHC in Hemodialysis Population. Target C (Rct)

Basu, Purba; Siriki, Ravi; Shah, Niraj James; Farhat, Sakina; Mittimani, Kavya; Atluri, Srilakshmi; Rahaman, Mostafizur; Brown, RM

doi:10.1016/s0168-8278(13)60069-0

Cited by 15 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies have focused on using interferon‐based treatments with or without ribavirin, in various dosages and frequencies . A handful of case reports and case series have explored the use of first generation protease inhibitors in combination with pegylated‐interferon and ribavirin in ESRD patients undergoing HD . The use of this regimen still presented unacceptable cure rates and similar toxicity issues to older regimens as they had interferon and ribavirin as backbone to the treatment.…”

mentioning

confidence: 99%

Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min

Nazario

Ndungu

Modi

2015

Liver International

107

View full text Add to dashboard Cite

Daily, full dose of sofosbuvir plus simeprevir for 12 weeks of therapy appears to be well tolerated in patients with ESRD on HD or GFR <30 ml/min. Most common AEs resembled those of healthier CHC patients without significant renal impairment. The cure rates obtained in this cohort treated with sofosbuvir and simeprevir are dramatically superior to any previous treatment regimen studied & published in this special patient population.

show abstract

mentioning

confidence: 99%

Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min

Nazario

Ndungu

Modi

2015

Liver International

107

View full text Add to dashboard Cite

show abstract

“…SVR rate was 63% for a 24-week treatment (12 þ 12) versus 25% in patients treated with PR [Basu et al 2013].…”

Section: Treatment Of Gt-1 Patients With Boceprevir or Telaprevir Beymentioning

confidence: 98%

An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials

Wendt

Bourlière

2013

Therapeutic Advances in Infection

View full text Add to dashboard Cite

The launch of first-generation protease inhibitors (PIs) was a major step forward in hepatitis C virus (HCV) treatment. However, this major advance is, up to now, restricted to genotype-1 (GT-1) patients. However, the ongoing development of new direct-acting antiviral agents (DAAs) allows new hope for the future. The development of second-wave and second-generation PIs yields higher antiviral potency through plurigenotypic activity, more convenient daily administration, fewer side effects and, for the second-generation PIs, potential activity against resistance-associated variants. NS5B inhibitors (NS5B.I) include nucleoside/nucleotide inhibitors (NIs) and nonnucleotide inhibitors (NNIs). NIs have high efficacy across all genotypes. Sofosbuvir has highly potent antiviral activity across all genotypes in association with pegylated interferon (IFN) and ribavirin (PR), thus allowing shortened treatment duration. NS5A inhibitors (NS5A.I) have highly potent antiviral activity. It has recently been shown for the first time that NS5A.I in combination with PI can cure GT-1b null-responder patients in an IFN-free regimen. In addition, several studies demonstrate that IFN-free regimens with DAA combinations are able to cure a large number of either naïve or treatment-experienced GT-1 patients. Moreover, a quadruple regimen with PR is able to cure almost all GT-1 null-responders. The development of pan-genotypic DAAs (NIs or NS5A.I) allows new combinations with or without PR that increase the rate of sustained virological response (SVR) for all patients, even for those with cirrhosis and independently of the genotype. Therefore, the near future of HCV treatment looks promising. The purpose of this article is to provide an overview of the clinical results recently reported for HCV treatment in GT-1 patients.

show abstract

“…Notably, patients with CrCl < 50 mL/min or those with ESRD were excluded from their registration trials [1] . Despite the lack of required dose adjustment, there have been very few small case series evaluating the safety and efficacy of these protease inhibitors in patients with ESRD on dialysis [65][66][67] . Therefore, the routine use of BOC/TVR-based triple therapy routine use in patients with severe renal impairment cannot be recommended [54,64] .…”

Section: Boceprevir-or Telaprevir-based Triple Therapymentioning

confidence: 99%

Management of patients with hepatitis C infection and renal disease

Bunchorntavakul

Maneerattanaporn

Chavalitdhamrong

2014

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection in patients with end-stage renal disease (ESRD) is associated with more rapid liver disease progression and reduced renal graft and patients' survival following kidney transplantation. Evaluations and management of HCV in patients with renal disease are challenging. The pharmacokinetics of interferons (IFN), ribavirin (RBV) and some direct acting antiviral (DAA), such as sofosbuvir, are altered in patients with ESRD. With dose adjustment and careful monitoring, treatment of HCV in patients with ESRD can be associated with sustained virological response (SVR) rates nearly comparable to that of patients with normal renal function. DAA-based regimens, especially the IFN-free and RBV-free regimens, are theoretically preferred for patients with ESRD and KT in order to increase SVR rates and to reduce treatment side effects. However, based on the data for pharmacokinetics, dosing safety and efficacy of DAA for patients with severe renal impairment are lacking. This review will be focused on the evaluations, available pharmacologic data, and management of HCV in patients with severe renal impairment, patients who underwent KT, and those who suffered from HCV-related renal disease, according to the available treatment options, including DAA.

show abstract

67 Telaprevir With Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and Treatment in CHC in Hemodialysis Population. Target C (Rct)

Cited by 15 publications

References 0 publications

Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min

Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min

An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials

Management of patients with hepatitis C infection and renal disease

Contact Info

Product

Resources

About